While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...

The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

Varadkar has been named as the Hauser Leader of the Harvard Kennedy School Center for Public Leadership for its spring ...

NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Texas Gov. Greg Abbott asked the federal government for $11 billion as a reimbursement for the border security measures he ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...

On the winning side of Wall Street were Novo Nordisk’s U.S.-listed shares, which jumped 8.5%. The Danish company reported ...

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Follow along for live updates on stocks, bonds and other markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

The latest health briefs reveal Novo Nordisk's promising obesity treatment and a $7.4 billion Purdue Pharma settlement over ...